Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results • Reported $420.5 million in cash resources as of March 31, 2024,which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 • Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) by our partner, Jazz Pharmac ...